Drugs / IN-207907
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07668180 | Sep 2026 → Feb 2028 expected | pelvic muscle wasting | HK inno.N Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN-207907 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07668180 ↗ |
| Route | Intravenous | “IN-207907 120 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.” NCT07668180 ↗ |